Symbols

KLRS

Kalaris·NASDAQ

--(--)

KLRS Profile

Kalaris Therapeutics, Inc.

A late-clinical stage allogeneic T-cell immunotherapy company that develops allogeneic, off-the-shelf VST therapies for devastating viral diseases

Industry

Biological Technology

Established Date

08/16/2013

Listing Date

07/30/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.kalaristx.com

Security Type

Common stock

Office address

400 Connell Drive, Suite 5500, Berkeley Heights, New Jersey

Business

Introduction

Kalaris Therapeutics, Inc., established on August 16, 2013, is a Delaware limited liability company. The Company is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for common retinal diseases with serious unmet medical needs. The Company is developing TH103, a novel clinical-stage anti-vascular endothelial growth factor (" VEGF ") drug specifically designed to achieve prolonged intraocular retention and enhanced VEGF inhibition in patients with exudative and neovascular retinal diseases.